atherosclerosis
Conditions
Interventions
Subjects in the intervention arm will receive daily 4 g of CLA oil (2.6 g
cis9,trans11-CLA), 2 capsules to be taken in the morning and 2 in the evening.
The subjects in the control arm receive 4 ide
Sponsors
Lipid Nutrition BV
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Healthy men and women Between 40-70 years of age Body mass index > 25 kg/m2
Exclusion criteria
Exclusion criteria: Indication or using blood pressure lowering drugs Indication or using lipid lowering drugs Indication or using glucose lowering drugs Symptomatic vascular disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study outcome is difference between treatment arms in change in aortic pulse wave velocity after 6 months intervention. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are differences between treatment groups in change in serum lipids (total, LDL- and HDL cholesterol, triglycerides) and change in systolic and diastolic blood pressure, as well as in platelet biomarkers of haemostatic function (proteonomics). Blood samples will be stored for assessment of plasma parameters of glucose intolerance, inflammation and endothelial function. | — |
Countries
Netherlands
Outcome results
None listed